A multifunctional DDS was achieved, which demonstrated the capability of successfully delivering candesartan and pAT2 into tumour cells, thus significantly inhibiting tumour growth and neovascularization in the A549 lung cancer model. This evidence concerns the gene SLC36A2 and neoplasm.